MyChesCo on MSN1 个月
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock
(NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C cardiogenic shock. This ...